WHO ICTRP trial
Prospective and open label study with blind end point evaluation on the effect…
EUCTR2010-018639-17-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2010-018639-17-DE |
|---|---|
| Public title | Prospective and open label study with blind end point evaluation on the effect of mineralcorticoid receptor inhibition on endothelial function of the micro- and macrovasculature in patient with metabolic syndrome |
| Scientific title | Prospective and open label study with blind end point evaluation on the effect of mineralcorticoid receptor inhibition on endothelial function of the micro- and macrovasculature in patient with metabolic syndrome |
| Primary sponsor | University Hospital Erlangen |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | Germany |
| Conditions | Metabolic syndrome MedDRA version: 12.1 Level: LLT Classification code 10052066 Term: Metabolic syndrome |
| Interventions | Trade Name: Inspra Pharmaceutical Form: Film-coated tablet |
| Registration date | Mar 25, 2010 |
| Target size | 42 |
| Secondary IDs | UR2010MSyn |
| Registry page | clinicaltrialsregister.eu |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: